As if ringing a dinner bell and saying "Come and get it!" Human Genome Sciences ($HGSI) has set a July 16 deadline for someone to come in and save it from the hostile takeover from its long-time partner GlaxoSmithKline ($GSK).
GlaxoSmithKline ($GSK) said it would and now it has. It extended its $2.6 billion hostile bid for shares of its partner Human Genome Sciences ($HGSI) by three weeks.
The latest on Amylin Pharmaceuticals' sales process: Four first-round bids. Four Big Pharma suitors. Offers ranging from $25 to $29 per share, valuing the company at up to $4.7 billion.
Human Genome Sciences ($HGSI) won a court battle in its hostile takeover fight with partner GlaxoSmithKline ($GSK), but faces an ever-expanding and ugly war.
Citing sources, Reuters says GSK has started scouting for candidates, and it could issue a solicitation to shareholders within a few weeks. The company would also extend its tender offer of $13 per share.
Human Genome Sciences has added a poison pill to its portfolio as it tries to fend off the hostile takeover by its longtime partner GlaxoSmithKline.
Prepare yourself for a drawn-out buyout battle--and lots of debate about the lupus treatment Benlysta.
In the wake of Roche's ($RHHBY) $5.7 billion hostile takeover bid for gene sequencing company Illumina ($ILMN), the jury is still out as to what it means for the industry at large. On the one hand,
The CEO of Canada's Valeant Pharmaceuticals has marshaled all of his arguments in favor of a hostile takeover of Cephalon ($CEPH) in a letter designed to woo shareholders, offering to bump the pharma
Valeant says it just might be willing to up its bid for Cephalon--once it gets its hands on the books for its due diligence work. Cephalon has been fending off Valeant's hostile acquisition effort,